Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study

Jorge L. Armenteros, John E. Lewis, Marisabel Davalos

Research output: Contribution to journalArticle

89 Scopus citations

Abstract

OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007

Original languageEnglish (US)
Pages (from-to)558-565
Number of pages8
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume46
Issue number5
DOIs
StatePublished - May 1 2007

Keywords

  • Aggression
  • Attention-deficit/hyperactivity disorder
  • Augmentation
  • Risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Fingerprint Dive into the research topics of 'Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study'. Together they form a unique fingerprint.

  • Cite this